| Dec 03 | Dec 02 | Dec 01 | |
|---|---|---|---|
| Income Statement | |||
| Total Revenue | |||
| Gross Profit | - | - | - |
| Operating Income | $ -862.54K | $ -2.28M | $ -2.24M |
| EBITDA | $ -862.54K | $ -2.23M | $ -1.01M |
| Net Income | $ -862.54K | $ -2.24M | $ -2.23M |
| Balance Sheet | |||
| Cash & Short-Term Investments | $ ― | $ ― | $ ― |
| Total Assets | $ 4.24M | $ 419.24K | $ 1.96M |
| Total Debt | $ 154.26K | $ 0.00 | $ 0.00 |
| Net Debt | $ 133.18K | $ -304.18K | $ -1.48M |
| Total Liabilities | $ 379.64K | $ 839.39K | $ 1.68M |
| Stockholders' Equity | $ ― | $ ― | $ ― |
| Cash Flow | |||
| Free Cash Flow | $ -769.51K | $ -2.68M | $ 114.35K |
| Operating Cash Flow | $ -769.51K | $ -2.66M | $ 145.61K |
| Investing Cash Flow | |||
| Financing Cash Flow |
Spencer Pharmaceutical Forecast EPS vs Actual EPS
Currently, no data available
Please return soon. This page is being updated.